Western genetic medicine makers turn to Chinese investigator-initiated trialsnews2025-12-15T12:30:18+00:00December 15th, 2025|Endpoints News|
House backs Biosecure Act aimed at Chinese companiesnews2025-12-11T09:52:38+00:00December 11th, 2025|Endpoints News|
D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3news2025-12-10T11:40:43+00:00December 10th, 2025|Endpoints News|
SanegeneBio raises $110M in follow-up to metabolic deal with Lillynews2025-12-09T16:43:39+00:00December 9th, 2025|Endpoints News|
Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiarynews2025-12-09T12:01:17+00:00December 9th, 2025|Endpoints News|
Biosecure Act appears headed for final passage in defense billnews2025-12-08T20:17:06+00:00December 8th, 2025|Endpoints News|
OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolionews2025-12-05T15:27:01+00:00December 5th, 2025|Endpoints News|
Crescent forms PD-1xVEGF, ADC pact with Kelun, raises $185Mnews2025-12-04T14:04:35+00:00December 4th, 2025|Endpoints News|
Pentagon seeks to add WuXi AppTec to military list: reportnews2025-12-02T20:19:07+00:00December 2nd, 2025|Endpoints News|
China’s Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturnanews2025-11-26T13:31:07+00:00November 26th, 2025|Endpoints News|
